SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001564590-18-021830
Filing Date
2018-08-15
Accepted
2018-08-15 16:10:24
Documents
4
Period of Report
2018-10-03
Effectiveness Date
2018-08-15

Document Format Files

Seq Description Document Type Size
1 DEF 14A kalv-def14a_20181003.htm DEF 14A 703599
2 GRAPHIC gnstsbdainwg000002.jpg GRAPHIC 72474
3 GRAPHIC gnstsbdainwg000001.jpg GRAPHIC 44737
4 GRAPHIC gnstsbdainwg000003.jpg GRAPHIC 96541
  Complete submission text file 0001564590-18-021830.txt   999776
Mailing Address ONE KENDALL SQUARE BUILDING 200, STE. 2203 CAMBRIDGE MA 02139
Business Address ONE KENDALL SQUARE BUILDING 200, STE. 2203 CAMBRIDGE MA 02139 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: DEF 14A | Act: 34 | File No.: 001-36830 | Film No.: 181021097
SIC: 2834 Pharmaceutical Preparations